Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.
Identifieur interne : 001E88 ( Ncbi/Merge ); précédent : 001E87; suivant : 001E89Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.
Auteurs : Nicholas Farinola [Australie] ; Neil PillerSource :
- Lymphatic research and biology [ 1539-6851 ] ; 2005.
Descripteurs français
- KwdFr :
- Aryl hydrocarbon hydroxylases (génétique), Coumarines (effets indésirables), Coumarines (pharmacologie), Coumarines (usage thérapeutique), Cytochrome P-450 CYP2A6, Flavonoïdes (pharmacologie), Humains, Lymphoedème (génétique), Lymphoedème (traitement médicamenteux), Mixed function oxygenases (génétique), Pharmacogénétique, Polymorphisme de nucléotide simple.
- MESH :
- effets indésirables : Coumarines.
- génétique : Aryl hydrocarbon hydroxylases, Lymphoedème, Mixed function oxygenases.
- pharmacologie : Coumarines, Flavonoïdes.
- traitement médicamenteux : Lymphoedème.
- usage thérapeutique : Coumarines.
- Cytochrome P-450 CYP2A6, Humains, Pharmacogénétique, Polymorphisme de nucléotide simple.
English descriptors
- KwdEn :
- Aryl Hydrocarbon Hydroxylases (genetics), Coumarins (adverse effects), Coumarins (pharmacology), Coumarins (therapeutic use), Cytochrome P-450 CYP2A6, Flavonoids (pharmacology), Humans, Lymphedema (drug therapy), Lymphedema (genetics), Mixed Function Oxygenases (genetics), Pharmacogenetics, Polymorphism, Single Nucleotide.
- MESH :
- chemical , adverse effects : Coumarins.
- chemical , genetics : Aryl Hydrocarbon Hydroxylases, Mixed Function Oxygenases.
- chemical , pharmacology : Coumarins, Flavonoids.
- chemical , therapeutic use : Coumarins.
- chemical : Cytochrome P-450 CYP2A6.
- drug therapy : Lymphedema.
- genetics : Lymphedema.
- Humans, Pharmacogenetics, Polymorphism, Single Nucleotide.
Abstract
Although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha pyrone), it would seem that targeted appropriate and monitored use of the drug does have a significant role in the treatment of lymphedemas. The particular benefits are its cost and ease of administration. Given today's demands for high level investigative clinical trials, it would be virtually impossible to conduct a study large enough to make any significant conclusions about hepatotoxic effects. However, it seems without doubt that the majority of studies conducted thus far suggest that coumarin (and other benzopyrones, i.e., the ruto-sides, which do not have hepatotoxic effects and which are often discussed in aggregate with coumarin) is effective in treating lymphedema, particularly when used in conjunction with complex physical therapy. The use of pharmacogenomics could significantly lower the risk of coumarin-associated hepatotoxicity, by targeting the use of coumarin to those with functional CYP2A6. Further research in this area will be required to re-evaluate the cost- benefit ratio and to determine the potential for the reintroduction of coumarin as a potent treatment for lymphedema. The perceived negative image of coumarin should not be allowed to carry across to the other benzopyrones, as they still confer a significant benefit in the management of lymphedemas.
DOI: 10.1089/lrb.2005.3.81
PubMed: 16000056
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003C45
- to stream PubMed, to step Curation: 003C45
- to stream PubMed, to step Checkpoint: 003C45
Links to Exploration step
pubmed:16000056Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.</title>
<author><name sortKey="Farinola, Nicholas" sort="Farinola, Nicholas" uniqKey="Farinola N" first="Nicholas" last="Farinola">Nicholas Farinola</name>
<affiliation wicri:level="2"><nlm:affiliation>Lymphedema Assessment Clinic, Department of Surgery, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide, South Australia.</nlm:affiliation>
<country>Australie</country>
<placeName><region type="state">Australie-Méridionale</region>
</placeName>
<wicri:cityArea>Lymphedema Assessment Clinic, Department of Surgery, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Piller, Neil" sort="Piller, Neil" uniqKey="Piller N" first="Neil" last="Piller">Neil Piller</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16000056</idno>
<idno type="pmid">16000056</idno>
<idno type="doi">10.1089/lrb.2005.3.81</idno>
<idno type="wicri:Area/PubMed/Corpus">003C45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003C45</idno>
<idno type="wicri:Area/PubMed/Curation">003C45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003C45</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003C45</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003C45</idno>
<idno type="wicri:Area/Ncbi/Merge">001E88</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.</title>
<author><name sortKey="Farinola, Nicholas" sort="Farinola, Nicholas" uniqKey="Farinola N" first="Nicholas" last="Farinola">Nicholas Farinola</name>
<affiliation wicri:level="2"><nlm:affiliation>Lymphedema Assessment Clinic, Department of Surgery, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide, South Australia.</nlm:affiliation>
<country>Australie</country>
<placeName><region type="state">Australie-Méridionale</region>
</placeName>
<wicri:cityArea>Lymphedema Assessment Clinic, Department of Surgery, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Piller, Neil" sort="Piller, Neil" uniqKey="Piller N" first="Neil" last="Piller">Neil Piller</name>
</author>
</analytic>
<series><title level="j">Lymphatic research and biology</title>
<idno type="ISSN">1539-6851</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aryl Hydrocarbon Hydroxylases (genetics)</term>
<term>Coumarins (adverse effects)</term>
<term>Coumarins (pharmacology)</term>
<term>Coumarins (therapeutic use)</term>
<term>Cytochrome P-450 CYP2A6</term>
<term>Flavonoids (pharmacology)</term>
<term>Humans</term>
<term>Lymphedema (drug therapy)</term>
<term>Lymphedema (genetics)</term>
<term>Mixed Function Oxygenases (genetics)</term>
<term>Pharmacogenetics</term>
<term>Polymorphism, Single Nucleotide</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Aryl hydrocarbon hydroxylases (génétique)</term>
<term>Coumarines (effets indésirables)</term>
<term>Coumarines (pharmacologie)</term>
<term>Coumarines (usage thérapeutique)</term>
<term>Cytochrome P-450 CYP2A6</term>
<term>Flavonoïdes (pharmacologie)</term>
<term>Humains</term>
<term>Lymphoedème (génétique)</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Mixed function oxygenases (génétique)</term>
<term>Pharmacogénétique</term>
<term>Polymorphisme de nucléotide simple</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Coumarins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Aryl Hydrocarbon Hydroxylases</term>
<term>Mixed Function Oxygenases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Coumarins</term>
<term>Flavonoids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Coumarins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Cytochrome P-450 CYP2A6</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Coumarines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Aryl hydrocarbon hydroxylases</term>
<term>Lymphoedème</term>
<term>Mixed function oxygenases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Coumarines</term>
<term>Flavonoïdes</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Coumarines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Pharmacogenetics</term>
<term>Polymorphism, Single Nucleotide</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Cytochrome P-450 CYP2A6</term>
<term>Humains</term>
<term>Pharmacogénétique</term>
<term>Polymorphisme de nucléotide simple</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha pyrone), it would seem that targeted appropriate and monitored use of the drug does have a significant role in the treatment of lymphedemas. The particular benefits are its cost and ease of administration. Given today's demands for high level investigative clinical trials, it would be virtually impossible to conduct a study large enough to make any significant conclusions about hepatotoxic effects. However, it seems without doubt that the majority of studies conducted thus far suggest that coumarin (and other benzopyrones, i.e., the ruto-sides, which do not have hepatotoxic effects and which are often discussed in aggregate with coumarin) is effective in treating lymphedema, particularly when used in conjunction with complex physical therapy. The use of pharmacogenomics could significantly lower the risk of coumarin-associated hepatotoxicity, by targeting the use of coumarin to those with functional CYP2A6. Further research in this area will be required to re-evaluate the cost- benefit ratio and to determine the potential for the reintroduction of coumarin as a potent treatment for lymphedema. The perceived negative image of coumarin should not be allowed to carry across to the other benzopyrones, as they still confer a significant benefit in the management of lymphedemas.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16000056</PMID>
<DateCreated><Year>2005</Year>
<Month>07</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>09</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1539-6851</ISSN>
<JournalIssue CitedMedium="Print"><Volume>3</Volume>
<Issue>2</Issue>
<PubDate><Year>2005</Year>
<Season>Summer</Season>
</PubDate>
</JournalIssue>
<Title>Lymphatic research and biology</Title>
<ISOAbbreviation>Lymphat Res Biol</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.</ArticleTitle>
<Pagination><MedlinePgn>81-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha pyrone), it would seem that targeted appropriate and monitored use of the drug does have a significant role in the treatment of lymphedemas. The particular benefits are its cost and ease of administration. Given today's demands for high level investigative clinical trials, it would be virtually impossible to conduct a study large enough to make any significant conclusions about hepatotoxic effects. However, it seems without doubt that the majority of studies conducted thus far suggest that coumarin (and other benzopyrones, i.e., the ruto-sides, which do not have hepatotoxic effects and which are often discussed in aggregate with coumarin) is effective in treating lymphedema, particularly when used in conjunction with complex physical therapy. The use of pharmacogenomics could significantly lower the risk of coumarin-associated hepatotoxicity, by targeting the use of coumarin to those with functional CYP2A6. Further research in this area will be required to re-evaluate the cost- benefit ratio and to determine the potential for the reintroduction of coumarin as a potent treatment for lymphedema. The perceived negative image of coumarin should not be allowed to carry across to the other benzopyrones, as they still confer a significant benefit in the management of lymphedemas.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farinola</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Lymphedema Assessment Clinic, Department of Surgery, School of Medicine, Flinders University and Flinders Medical Centre, Adelaide, South Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Piller</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Lymphat Res Biol</MedlineTA>
<NlmUniqueID>101163587</NlmUniqueID>
<ISSNLinking>1539-6851</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003374">Coumarins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A4VZ22K1WT</RegistryNumber>
<NameOfSubstance UI="C030123">coumarin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.-</RegistryNumber>
<NameOfSubstance UI="D006899">Mixed Function Oxygenases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="C585710">CYP2A6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D065637">Cytochrome P-450 CYP2A6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065637" MajorTopicYN="N">Cytochrome P-450 CYP2A6</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006899" MajorTopicYN="N">Mixed Function Oxygenases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>18</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16000056</ArticleId>
<ArticleId IdType="doi">10.1089/lrb.2005.3.81</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
<region><li>Australie-Méridionale</li>
</region>
</list>
<tree><noCountry><name sortKey="Piller, Neil" sort="Piller, Neil" uniqKey="Piller N" first="Neil" last="Piller">Neil Piller</name>
</noCountry>
<country name="Australie"><region name="Australie-Méridionale"><name sortKey="Farinola, Nicholas" sort="Farinola, Nicholas" uniqKey="Farinola N" first="Nicholas" last="Farinola">Nicholas Farinola</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001E88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16000056 |texte= Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16000056" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |